Investor Presentation - First Six Months of 2021

68 Novo Nordisk® Biopharm sustained growth outlook is supported by innovation and utilisation of core capabilities Investor presentation First six months of 2021 Internal and external innovation to drive long-term growth H Core capabilities within research and development to drive long-term growth 24 Bringing internal innovation to market by pipeline progression Ensuring future growth by leveraging external innovation Exploring new technologies by utilising added research platforms Leveraging deep biological understanding for future growth

View entire presentation